INDIANAPOLIS, June 17, 2021 /PRNewswire/ -- Based on
results from a large population-based survey, it is estimated that
approximately half of people with migraine hesitate to seek care
for a variety of reasons, and even fewer receive a diagnosis and
take the treatment they need.1,2,3 To help address
these important unmet needs in migraine care, Eli Lilly and Company
(NYSE: LLY) launched Think Talk Treat Migraine™, a new initiative
to empower people living with migraine and their primary care
providers to recognize key symptoms of migraine and have better
conversations about the disease that can lead to proper diagnosis
and treatment.
The initiative is currently in pilot stage – available in four
metropolitan areas – Hartford/New
Haven (Connecticut),
Raleigh/Durham (North Carolina), Indianapolis (Indiana) and Denver
(Colorado) – and provides people living with migraine and
their healthcare providers with simple resources to think
about, talk about and treat migraine.
"People with significant disabling headache often do not
recognize it as migraine and as a result, understandably do not
seek care. Further, among those who do seek care, there is often a
gap in communication between them and their primary care provider,
particularly about the impact migraine has on their life. This can
not only lead to fewer appropriate diagnoses, but also treatment
recommendations that may not deliver the freedom from migraine pain
they seek," said Michael Cobas
Meyer, MD, MBA, vice president of global medical affairs,
Lilly Bio-Medicines. "The goal of Think Talk Treat Migraine is to
simplify the recognition and discussion of the disease from both
the patient and the primary care provider perspectives, potentially
leading to meaningful improvements in health outcomes through
accurate diagnosis and appropriate, timely care."
More people impacted by migraine seek care from a primary
care provider than any other care setting,4 yet research
shows that only a small proportion receive a migraine diagnosis and
treatment recommendation during those initial
discussions.5 There can be many reasons for this
including the short length of an office visit or the ability to
effectively convey or recognize symptoms.6 While 40% of
people with migraine are eligible for preventive treatment, less
than 20% receive it.7 Further, only 28% of people
impacted by migraine and eligible for acute treatment are seeking
care, diagnosed with migraine and prescribed recommended acute
medication.3
"I've been living with migraine for most of my adult life and
like many others who may be misdiagnosed or undiagnosed, I didn't
realize there was a name for what I was experiencing or that it was
a neurological disease," said Kelsey V., 27 years old from
Colorado. "It's important that initial discussions about migraine
with one's health care provider are easier because having the right
diagnosis and the right treatment can make all the difference."
Think Talk Treat Migraine provides information, tools and
resources specifically developed for people who may be living with
migraine and primary care providers, including a Talk To Your
Healthcare Provider Checklist, a new digital migraine management
platform called VEGA™ and education about the ID
Migraine® tool, which helps identify people living
with migraine by asking three simple questions:
- Has a headache limited your activities any day in the last
month?
- Are you nauseated or sick to your stomach when you have a
headache?
- Does light bother you when you have a headache?
Research has shown that if a person experiencing headaches
answers yes to two of these questions, there is a greater than 90%
chance they are living with migraine and should speak with their
healthcare provider.8
VEGA is a digital platform that offers a smartphone app to
enable users to track important information about their migraine
such as their ability to function, pain severity, symptoms,
triggers and the medications they take to manage it. With this
information, a person can more effectively talk to their provider
about the impact migraine has on their life, which may help inform
an appropriate treatment plan.
Think Talk Treat Migraine will also host webinars for
primary care providers to help elevate awareness of migraine within
the primary care setting. Information provided during the webinars
will focus on a streamlined approach to help identify migraine,
information about how to assess the impact of migraine and insights
about how the extent of impact a migraine has can inform an
appropriate treatment plan.
"Despite its prevalence and the human and societal impact of
migraine, this disease is often underestimated and misunderstood. A
variety of reasons, including stigma and lack of awareness, drive
some people living with migraine to hide their pain and the effects
of the disease. This can lead to underdiagnoses and unnecessary
pain and disability," said Kevin
Lenaburg, executive director, Coalition for Headache and
Migraine Patients (CHAMP). "Lilly understands the impact that
not getting an accurate diagnosis can have on people living with
migraine and recognizes that it doesn't have to be that way. Think
Talk Treat Migraine is fostering important conversations while
providing the tools and resources to help make a meaningful
difference for people with migraine and primary care providers
alike."
About Migraine
Migraine is a severely disabling
neurologic disease characterized by recurrent episodes of moderate
to severe headache accompanied by other symptoms including nausea,
sensitivity to light, and sensitivity to
sound.9,10 More than 30 million American adults
have migraine, with three times more women than men affected by
migraine.7 Migraine is often incapacitating,
leading to high personal, societal, and economic burden. According
to the Medical Expenditures Panel Survey, total annual healthcare
costs associated with migraine are estimated to be as high as
$56 billion in the United States, yet it remains
under-recognized and under-treated.11
About Lilly's Commitment to Headache Disorders
For
over 25 years, Lilly has been committed to helping people affected
by headache disorders, investigating more than a dozen different
compounds for the treatment of migraine and cluster headache. These
research programs have accelerated our understanding of these
diseases and furthered the advancement of treatments for headache
disorders. Our goal is to apply our combined clinical, academic and
professional experience to build a research portfolio that delivers
broad solutions and addresses the needs of people affected by these
disabling neurologic diseases.
About Eli Lilly and Company
Lilly is a global
health care leader that unites caring with discovery to create
medicines that make life better for people around the world. We
were founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
lilly.com and lilly.com/newsroom. C-LLY
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995) about Lilly's Think Talk Treat
Migraine™ Initiative and Lilly's efforts, plans, and objectives,
and reflects Lilly's current beliefs and expectations. There can be
no assurance that Lilly will be successful in achieving the goals
discussed above. For additional information about the factors that
could cause actual results to differ materially from
forward-looking statements, see Lilly's Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
Think Talk Treat Migraine™ and VEGA™
are trademarks owned or licensed by Eli Lilly and Company, its
subsidiaries, or affiliates.
ID Migraine® is a registered trademark of Pfizer
Inc.
References
- Shapiro RE, Nicholson RA, Zagar AJ, Reed ML, Buse DC,
Hutchinson S, Ashina S, Lombard LA, Pearlman EM, Lipton RB. et al,
Reasons for Hesitating to Consult for Migraine Care: Results of the
Observational Survey of the Epidemiology, Treatment and Care of
Migraine (U.S.) (OVERCOME) Study. Headache. 2021;61(S1):10-11
- Ashina S, Nicholson RA, Buse DC, Reed ML, Vargas B, Hutchinson
S, Samaan K, Zagar A, Kim Y, Pearlman EM, Lipton RB. Identifying
barriers to care-seeking, diagnosis, and preventive medication
among those with migraine: results of the OVERCOME study. Headache.
2020;60(S1):127-128.
- Nicholson RA, Hutchinson S, Vargas B, Buse DC, Reed ML, Ashina
S, Samaan K, Zagar A, Kim Y, Pearlman EM, Lipton RB. Seeking care,
diagnosis, and acute prescription for migraine among those with
headache-related disability: results of the OVERCOME study.
Headache. 2020;60(S1):132-133.
- Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and
burden of migraine and severe headache in the United States: updated statistics from
government health surveillance studies. Headache. 2015
Jan;55(1):21-34. doi: 10.1111/head.12482. Erratum in: Headache.
2015 Feb;55(2):356. PMID: 25600719.
- Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML,
Schwedt TJ, Dodick DW. Migraine in America Symptoms and Treatment
(MAST) Study: Baseline Study Methods, Treatment Patterns, and
Gender Differences. Headache. 2018 Oct;58(9):1408-1426. doi:
10.1111/head.13407. Epub 2018 Oct 20. PMID: 30341895.
- Martin, VT. 5 great reasons why you, a primary care clinician,
should develop additional expertise in the field of headache
medicine (AHS). Available at:
https://americanheadachesociety.org/wp-content/uploads/2021/01/AHS-First-Contact-5-Reasons-to-get-Headache-Expertise.pdf.
Accessed: May 20, 2021.
- Lipton RB, Bigal ME, Diamond M, et al., Migraine prevalence,
disease burden, and the need for preventive therapy. Neurology.
2007;68:343-349.
- Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J,
Hettiarachchi J, Harrison W; ID Migraine validation study. A
self-administered screener for migraine in primary care: The ID
Migraine validation study. Neurology. 2003 Aug 12;61(3):375-82.
doi: 10.1212/01.wnl.0000078940.53438.83. PMID: 12913201.
- Katsarava Z, Buse D, Manack A, et al. Defining the differences
between episodic migraine and chronic migraine. Current Pain
Headache Reports. 2012;16:86.
- Blumenfeld AM, Payne KA, Varon SF, et al. Disability, HRQOL,
and resource use amongst chronic and episodic migraineurs. Results
from the International Burden of Migraine Study (IBMS).
Cephalalgia. 2011;31:301.
- Raval AD, Shah A. National trends in direct health care
expenditures among US adults with migraine: 2004 to 2013. Journal
of Pain. 2017;57:60.
Refer to: Jen Dial;
dial_jennifer_kay@lilly.com; 317-220-1172 (Lilly Bio-Medicines)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-launches-think-talk-treat-migraine-to-help-improve-diagnosis-and-treatment-of-migraine-301314639.html
SOURCE Eli Lilly and Company